ATRC240517P50000
- 21.00
- 0.000.00%
AtriCure Newsroom
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
AtriCure, Inc. ((
AtriCure Enhances Governance and Expands Stock Plan
AtriCure (NASDAQ:ATRC Shareholders Incur Further Losses as Stock Declines 9.8% This Week, Taking Three-year Losses to 73%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of AtriCure, Inc. (NASDAQ:AT
AtriCure, Inc. (NASDAQ:ATRC) Just Reported, And Analysts Assigned A US$47.33 Price Target
AtriCure(ATRC.US) Officer Sells US$36,135 in Common Stock
$AtriCure(ATRC.US)$ Officer Noznesky Justin J sold 1,500 shares of common stock on May 1, 2024 at an average price of $24.09 for a total value of $36,135.Source: Announcement What is statement of chan
The Past Three Years for AtriCure (NASDAQ:ATRC) Investors Has Not Been Profitable
AtriCure Price Target Cut to $49.00/Share From $57.00 by Canaccord Genuity
AtriCure Price Target Cut to $49.00/Share From $57.00 by Canaccord Genuity
AtriCure, Inc. (NASDAQ:ATRC) Q1 2024 Earnings Call Transcript
Express News | AtriCure Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Adjusted EPS Results. Also, Needham Maintained a Buy Rating on the Stock and Lowered Its Price Target From $46 to $40
AtriCure Is Maintained at Overweight by JP Morgan
AtriCure Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $34
Earnings Call Summary | AtriCure(ATRC.US) Q1 2024 Earnings Conference
The following is a summary of the AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript:Financial Performance:AtriCure's Q1 2024 overall revenue was $109 million, up 16% from Q1 2023.Gross margin rea
Cracking The Code: Understanding Analyst Reviews For AtriCure
In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasing the evol
Earnings Call: AtriCure Reports Robust Q1 2024 Growth, Reaffirms Guidance
AtriCure Is Maintained at Buy by Needham
AtriCure Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on AtriCure, Lowers Price Target to $40
AtriCure Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 71.67% Needham $46 → $40 Maintains Buy 04/23/2024 37.34% Oppenheimer → $32 Upgrades Perform → O
Express News | AtriCure Inc : Canaccord Genuity Cuts Target Price to $49 From $57
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
Express News | AtriCure Inc : JP Morgan Cuts Target Price to $34 From $42